https://scholars.lib.ntu.edu.tw/handle/123456789/543491
標題: | A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer | 作者: | Chao Y. Hsieh J.-S. Yeh H.-T. Su Y.-C. Wu C.-C. Chen J.-S. Tai C.-J. Bai L.-Y. KUN-HUEI YEH Su W.-C. Li C.-P. |
公開日期: | 2014 | 出版社: | Springer Verlag | 卷: | 73 | 期: | 4 | 起(迄)頁: | 799-806 | 來源出版物: | Cancer Chemotherapy and Pharmacology | 摘要: | Purpose: We evaluated the safety and efficacy of biweekly capecitabine in combination with oxaliplatin in previously untreated patients with locally advanced or metastatic gastric cancer. Methods: Patients received oral capecitabine 1,000 mg/m2 twice daily on days 1-10 plus oxaliplatin 85 mg/m2 as a 2-h intravenous infusion on day 1, every 2 weeks (XELOX). The primary endpoint was overall response rate. Secondary endpoints included progression-free survival, overall survival, and toxicity. Results: From March 2007 to October 2010, 46 patients were enrolled in this phase II study. The median age was 64 years (range 32-85). A total of 391 (median 7.5, range 1-29) cycles were delivered. Among the 41 patients evaluable for tumor response, 9 showed partial response and 25 had stable disease. The overall response rates of the evaluable and intent-to-treat (ITT) populations were 22 % (95 % CI 10-42 %) and 20 % (95 % CI 9-34 %), respectively. In the ITT analysis, the progression-free survival and overall survival were 5.6 months (95 % CI 4.1-6.3 months) and 8.0 months (95 % CI 6.3-10.1 months), respectively. The most common hematological toxicities were thrombocytopenia (35 %) and leucopenia (34 %), whereas the most common non-hematological toxicities were neuropathy (35 %), fatigue (33 %), diarrhea (27 %), vomiting (26 %), and hand-foot syndrome (25 %). Major grade 3-4 toxicities were anemia (11 %), diarrhea (9 %), and hand-foot syndrome (7 %). No patient died of treatment-related toxicities. Conclusions: Although the biweekly XELOX regimen failed its primary response rate endpoint, it showed modest efficacy and an acceptable safety profile in the treatment of advanced gastric cancer. ? 2014 The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84898058566&doi=10.1007%2fs00280-014-2407-y&partnerID=40&md5=1af9a8f3a12cba7d878cb6f87ea6b58d https://scholars.lib.ntu.edu.tw/handle/123456789/543491 |
ISSN: | 0344-5704 | DOI: | 10.1007/s00280-014-2407-y | SDG/關鍵字: | anthracycline; capecitabine; cetuximab; cisplatin; cyclophosphamide; everolimus; fluoropyrimidine; fluorouracil; irinotecan; oxaliplatin; paclitaxel; tegafur; uracil; abdominal distension; abdominal pain; adult; advanced cancer; aged; anorexia; article; body weight disorder; cancer combination chemotherapy; cancer localization; cancer survival; chemotherapy induced anemia; clinical article; constipation; controlled study; diarrhea; disease control; dizziness; drug efficacy; drug fever; drug safety; drug withdrawal; edema; fatigue; female; follow up; hand foot syndrome; human; hypertension; insomnia; intention to treat analysis; leukopenia; male; monotherapy; mucosa inflammation; multicenter study; multiple cycle treatment; nausea; neuropathy; neutropenia; overall survival; phase 2 clinical trial; pitting edema; population; priority journal; progression free survival; stomach cancer; Taiwan; therapy delay; thrombocytopenia; treatment duration; treatment response; very elderly; vomiting; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Stomach Neoplasms |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。